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Abstract
Metastatic lesion of the pancreas originated from other organs is uncommon. The aim of this report was to evaluate
the outcome of surgery in patients with isolated metastases to the pancreas. Nine patients underwent pancreatic
resection for metastatic malignant disease from 2000 to 2015 at the Department of Gastroenterological Surgery of the
Kumamoto University Hospital. The primary lesion was renal cell carcinoma in 7 cases, colon cancer in 1 and malignant
melanoma in 1. The median interval from the initial operation to pancreatic resection was 138 months. Operative
procedure was distal pancreatectomy in 6 cases, pancreaticoduodenectomy in 2 and total pancreatectomy in 1. Two
patients with renal cell carcinoma and 1 patient with malignant melanoma died 131, 108, and 4 months after the
pancreatic resection, respectively. Other 6 patients have survived until now with 23.5 months of observation periods
after pancreatic resection. In conclusion, pancreatic metastasis can develop years after the treatment of primary lesion.
Pancreatic resection can achieved long-term survival, at least in the patients who had primary renal carcinoma.
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Background
Most pancreatic tumors are primary pancreatic adenocar-
cinoma. However, metastatic pancreatic tumor can be de-
veloped from renal cell cancer, lung, breast, colon, or skin
tumors [1–7]. Metastasis to the pancreas is rare, accounts
for less than 2% of all pancreatic malignancies [3, 4, 8–11]
and can be generally developed synchronous or metachro-
nous and single or multiple. In addition, a previous large
autopsy series indicated that the prevalence of pancreatic
metastases was 6 to 11%, and renal cell carcinoma was the
most common primary tumor to cause metastatic pancre-
atic tumors [12].
Experience with resections of pancreas for the isolated
metastatic lesions is very limited [3, 6–8, 10, 11, 13, 14],
because metastatic disease to the pancreas is considered
to exist commonly with metastasis to other organs such
as the liver and lung [1]. As a result, the value of surgical
treatment to the metastasis to the pancreas is unclear,
and there are no guidelines or recommended strategies
regarding the appropriate management of such lesions.
The aim of this report was to evaluate the outcome of
surgery in patients with metastases to the pancreas.
Case presentation
Patients’ characteristics, primary tumors, and other
metastasis before pancreatic metastasis
Nine patients underwent pancreatic resection for meta-
static malignant disease from 2000 to 2015 at the Depart-
ment of Gastroenterological Surgery of the Kumamoto
University Hospital. The patients included 5 males and 4
females, with a median age of 66 years (range, 52–83) at
the pancreatic surgery (Table 1). The primary lesion, clear
cell renal cell carcinoma (RCC) (right kidney in 3, left in 3,
and bilateral in 1), 1 rectal cancer (tubular adenocarcin-
oma), and 1 oral malignant melanoma (MM), was resected
in all cases.
Before the emergence of the pancreatic metastasis, 2 pa-
tients experienced metastasis of the other organs (Table 1).
Bilateral multiple lung metastasis from RCC was developed
in case no. 5, 10 months before the pancreatic metastasis. It
was treated by axitinib, followed by sunitinib, and archived
partial response (PR). In this case, the lung metastases were
well-controlled by chemotherapy. However, pancreatic
metastasis was growing, and so distal pancreatectomy was
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performed. A solitary right lung metastasis from rectal can-
cer in case no. 7 was resected 76 months before the pancre-
atic metastasis.
Characteristics of the pancreatic metastasis and results of
the pancreatic surgery
The median interval from the initial surgery to the
emergence of the pancreatic metastasis of the whole
cases was 138 months (range, 0–228). The interval was
138 months (range, 0–228) in RCC patients, 154 months
in a rectal cancer patient, and 5 months in a MM pa-
tient, respectively (Table 2). Pancreatic metastasis was
solitary in 6 cases and multiple in 3 cases and existed in
the head in 2 cases, in the body–tail in 6 cases, and in
the whole pancreas in 1 (case no. 7). Interestingly, me-
tastasis from the left kidney was developed in pancreatic
body–tail in all cases (nos. 1, 3, and 5). The median size
of the largest pancreatic metastasis was 28 mm (range,
10–39). In case no. 6, whereas the pancreatic tumor was
only 10 mm (Fig. 1a), it could be preoperatively diag-
nosed as metastasis from clear cell RCC by endoscopic
ultrasound-guided fine needle aspiration (EUS-FNA)
(Fig. 1b, c).
Operative procedure was distal pancreatectomy (DP)
in 6 cases, pancreaticoduodenectomy (PD) in 2 cases
(pylorus-preserving pancreaticoduodenectomy (PPPD)
in 1 and subtotal stomach-preserving pancreaticoduode-
nectomy (SSPPD) in 1), and total pancreatectomy (TP)
in 1 case (Table 2, Fig. 2a, b). Median operative time
was 328 min (range, 241–472), and median operative
blood loss was 580 g (range, 136–2587). Postoperative
complication was observed in 3 (33.3%), grade B of
postoperative pancreatic fistula (POPF) in 2, and
delayed gastric emptying (DGE) in 1. There was no







Primary tumors Other metastasis before pancreatic metastasis
Location Treatment Histology Location Treatment
1 61/F Left kidney Resection Clear cell RCC – –
2 52/M Bilateral kidney Resection Clear cell RCC – –
3 67/F Left kidney Resection Clear cell RCC – –
4 83/M Right kidney Resection Clear cell RCC – –
5 66/M Left kidney Resection Clear cell RCC Bilateral lung Axitinib→ Sunitinib
6 69/F Right kidney Resection Clear cell RCC – –
7 55/F Right kidney Resection Clear cell RCC
8 72/M Rectum Resection Tubular adenocarcinoma Right lung Resection
9 55/M Oral cavity Resection Malignant melanoma – –
RCC renal cell carcinoma


















1 60 Tail 2 14, 25 DP 241 467 None Clear cell RCC
2 0 Head 1 36 PPPD 448 710 DGE Clear cell RCC
3 138 Body–tail 3 17, 22,
28
DP 299 580 None Clear cell RCC
4 156 Body–tail 1 30 DP 328 136 None Clear cell RCC
5 228 Tail 1 39 DP 440 2587 None Clear cell RCC
6 144 Head 1 10 SSPPD 472 745 POPF Clear cell RCC
7 26 Head–
body–tail
6 6~20 TP 406 1176 None Clear cell RCC
8 154 Tail 1 35 DP 324 445 POPF Tubular
adenocarcinoma
9 5 Body–tail 1 28 DP 263 356 None Malignant
melanoma
Interval months from the initial surgery to the operation for the pancreatic metastasis, DGE delayed gastric emptying, DP distal pancreatectomy, POPF
postoperative pancreatic fistula, PPPD pylorus-preserving pancreaticoduodenectomy, RCC renal cell carcinoma, SSPPD subtotal stomach-preserving
pancreaticoduodenectomy, TP total pancreatectomy
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hospital death. Pathological diagnoses of the pancre-
atic tumors were consistent with those of the primary
lesion in all cases (Fig. 2c).
Other metastasis after pancreatic metastasis and long-
term outcome
Bilateral multiple lung metastasis existed in 3 patients
with metastasis from RCC, and 2 cases of them were
treated by combination of interferon (IFN), interleukin-2
(IL-2), and tegafur-uracil (UFT) or sunitinib, respectively
(Table 3). Bilateral multiple lung metastasis and bone
metastasis developed in a patient with metastasis from
MM, treated by dacarbazine.
Two patients with metastasis from RCC and 1 patient
with metastasis from MM died 131, 108, and 4 months
after the pancreatic resection, respectively. Other 6
patients have survived until now with 23.5 months
(range, 3–138) of observation periods after pancreatic
resection.
Conclusions
The pancreas is an unusual but occasionally favored site
for metastasis, notably from carcinoma of the kidney and
lung [1–3, 15]. In this series of the patients, 77.8% (case
nos. 1–7) pancreatic tumor were metastasis from clear cell
RCC and 11.1% (case no. 7) were from rectal cancer,
consistent with previous studies [4–7]. Interestingly, all
metastatic tumors from the left RCC (3 cases) were devel-
oped in the left side of the pancreas. This tendency of
metastatic direction to the pancreas has been never
reported and may indicate the mechanism of
hematogenous metastasis from the kidney to pancreas. In
patients with portal hypertension, vascular endothelial
growth factor (VEGF)-dependent angiogenesis plays a
crucial role in the formation of portal-systemic collateral
vessels, which include spleno-renal shunts [16]. VEGF has
an important role in progression of RCC [17]. Collateral
vessels like spleno-renal shunts dependent on VEGF
angiogenesis possibly contribute to the tendency of meta-
static direction in RCC patients. One case of our series
was the metastasis from oral malignant melanoma, with
poor prognosis even the aggressive chemotherapy by
dacarbazine. There were a few reports indicated similar
situation [18, 19]; however, it appears that surgical
resection is only a palliative procedure, because long-term
survival is a rare event.
Despite the technological advances, preoperative
diagnosis of the metastatic pancreatic tumor is sometimes
difficult [15]. EUS-FNA is an excellent method for pro-
curement of diagnostic samples from the pancreas, with a
diagnostic accuracy of more than 90% for pancreatic
adenocarcinoma [20, 21]. One patient in this study (case
no. 6) was preoperatively diagnosed as metastasis of clear
cell RCC by EUS-FNA, even only 10 mm of the size of the
Fig. 1 Preoperative findings of case no. 6. Enhanced CT (a) and EUS
(b) revealed 10-mm tumor (arrowheads) in the pancreatic head of
case no. 6. It was preoperatively diagnosed as metastasis from clear
cell RCC (c) by EUS-FNA
Fig. 2 Operative and histological findings of case no. 6. SSPPD (a)
was performed in case no. 6. Histologically, the tumor (arrowheads)
(b) was confirmed as the metastasis from clear cell RCC (c)
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tumor. It suggested that EUS-FNA is useful to correct
diagnosis of metastatic pancreatic tumor.
Surgical resection of the metastatic tumor to the pancreas
should be approached by carefully applying appropriate
selection criteria, because of the substantial morbidity indi-
cated in this series and a previous report [22]. On the other
hand, a noteworthy finding in our series was a long interval
from the initial surgery to the pancreatic metastasis and
long survival after pancreatic resection. This was particu-
larly the cases with clear cell RCC patients. Yuasa et al.
reported that the median duration from diagnosis of RCC
to pancreatic metastasis was 7.8 years (4.2–12.7 years) [23].
Consistent with the study, metastatic tumor of the pancreas
from RCC is recurred in long-term interval in general in
our series. Patients with isolated RCC metastasis to the
pancreas, whether synchronous or metachronous, represent
a selected group of patients with more indolent RCC [22].
In addition, new effective therapeutic strategy such as
molecular target drug has been introduced to metastatic
disease from clear cell RCC [24]. This advantage may pro-
vide the benefit of resection of the pancreatic metastasis
even with metastatic lesions in other organs such as the
lung, in selected cases with good response to the treatment,
as indicated in our study.
We performed distal pancreatectomy in 6 cases,
pancreaticoduodenectomy in 2 cases, and total pancrea-
tectomy in 1 case. The surgical strategy for pancreatic
metastatic tumor has not been established. Recently,
limited or partial pancreatectomy has been performed,
especially for disease which does not need lymph node
dissection [25]. These preserving operations may be
useful for patients with pancreatic metastasis from clear
cell renal cell carcinoma.
In conclusion, the metastasis to the pancreas can be
developed years after the initial surgery of the primary
disease. EUS-FNA was suggested to be feasible for
diagnosis and helpful to consider the indication of
surgery. Long-term survival can be archived with pan-
creatic resection, especially in patients with pancreatic
metastasis from clear cell RCC.
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Table 3 Other metastasis after pancreatic metastasis and long-term outcome





1 Bilateral lung None (BSC) 131a
2 Bilateral lung IFN + IL-2 + UFT 108a
3 – – 138
4 – – 49
5 Bilateral lung Sunitinib 8
6 – – 8
7 – – 3
8 – – 39
9 Bilateral lung, bone Dacarbazine 4a
Postoperative observation period months after the operation for the pancreatic metastasis, BSC best supportive care, IFN interferon, IL-2 interleukin-2,
UFT tegafur-uracil
aDead
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